Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C15H23N3O4S.ClH |
| Molecular Weight | 377.887 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN1CCCC1CNC(=O)C2=C(OC)C=CC(=C2)S(N)(=O)=O
InChI
InChIKey=PFHZICSPLHQCDZ-UHFFFAOYSA-N
InChI=1S/C15H23N3O4S.ClH/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2;/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21);1H
| Molecular Formula | C15H23N3O4S |
| Molecular Weight | 341.426 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/6628519
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/6628519
Sulpiride is an atypical antipsychotic drug (although some texts have referred to it as a typical antipsychotic) of the benzamide class used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression. Sulpiride is commonly used in Europe, Russia and Japan. Sulpiride is a selective antagonist at dopamine D2 and D3 receptors. This action dominates in doses exceeding 600 mg daily. In doses of 600 to 1,600 mg sulpiride shows mild sedating and antipsychotic activity. Its antipsychotic potency compared to chlorpromazine is only 0.2 (1/5). In low doses (in particular 50 to 200 mg daily) its prominent feature is antagonism of presynaptic inhibitory dopamine receptors accounting for some antidepressant activity and a stimulating effect. Therefore, it is in these doses used as a second line antidepressant. Racemic and L-sulpiride significantly decreased stimulated serum gastrin concentration, but they did not affect fasting serum gastrin or basal and stimulated gastric acidity. D-sulpiride significantly decreased gastric acid secretion, without affecting serum gastrin levels.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL217 |
10.28 nM [IC50] | ||
Target ID: CHEMBL234 |
66.22 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Eglonyl Approved UseIndications. Acute and chronic psychosis (confusion, delirium, confusion, agrammatism, abulia), schizophrenia; neurotic state, accompanied by lethargy; psychosomatic symptoms (especially for stomach ulcers and duodenal ulcers and hemorrhagic rektokolite). |
|||
| Primary | Eglonyl Approved UseIndications. Acute and chronic psychosis (confusion, delirium, confusion, agrammatism, abulia), schizophrenia; neurotic state, accompanied by lethargy; psychosomatic symptoms (especially for stomach ulcers and duodenal ulcers and hemorrhagic rektokolite). |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Nicotine potentiates sulpiride-induced catalepsy in mice. | 1998 |
|
| Asthma precipitated by cessation of lithium treatment. | 1999 Oct |
|
| Choreic movements induced by cibenzoline: an Ic class antiarrhythmic effect? | 2000 Sep |
|
| Short-term modulation of prolactin secretion by melatonin in anestrous ewes following dopamine- and opiate receptor blockade. | 2001 |
|
| Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia. | 2001 |
|
| SCH 23390 affords protection against soman-evoked seizures in the freely moving guinea-pig: a concomitant neurochemical, electrophysiological and behavioural study. | 2001 |
|
| In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. | 2001 Apr |
|
| Effects of dopamine and dopamine-active compounds on oxytocin and vasopressin production in rat neurohypophyseal tissue cultures. | 2001 Apr 2 |
|
| Effect of dopamine D2/D3 receptor antagonist sulpiride on amphetamine-induced changes in striatal extracellular dopamine. | 2001 Apr 27 |
|
| A method to evaluate the diffusion rate of drugs from a microdialysis probe through brain tissue. | 2001 Aug 15 |
|
| Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. | 2001 Aug 15 |
|
| A dopaminergic mechanism is involved in the 'anxiogenic-like' response induced by chronic amphetamine treatment: a behavioral and neurochemical study. | 2001 Aug 3 |
|
| Intra-supraoptic nucleus sulpiride improves anorexia in tumor-bearing rats. | 2001 Aug 8 |
|
| Hypothalamic dopaminergic receptor expressions in anorexia of tumor-bearing rats. | 2001 Dec |
|
| The changes of biological markers and treatment efficacy in schizophrenia. | 2001 Feb |
|
| Reversal effect of sulpiride on rotational behaviour of rats with unilateral frontal cortex ablation: an alternative explanation for the pharmacological mechanism of its antidepressant effect. | 2001 Feb |
|
| Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. | 2001 Feb |
|
| Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause. | 2001 Feb |
|
| Evidence for a modulatory role of Ih on the firing of a subgroup of midbrain dopamine neurons. | 2001 Feb 12 |
|
| Changes in striatal electroencephalography and neurochemistry induced by kainic acid seizures are modified by dopamine receptor antagonists. | 2001 Feb 16 |
|
| Negative interaction of dopamine D2 receptor antagonists and GBR 12909 and GBR 12935 dopamine uptake inhibitors in the nucleus accumbens. | 2001 Feb 23 |
|
| Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study. | 2001 Jan |
|
| Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. | 2001 Jan |
|
| Pharmacology of [3H]R(+)-7-OH-DPAT binding in the rat caudate-putamen. | 2001 Jan |
|
| Improved intestinal absorption of sulpiride in rats with synchronized oral delivery systems. | 2001 Jan 29 |
|
| Helium-oxygen pressure induces striatal glutamate increase: a microdialysis study in freely-moving rats. | 2001 Jan 5 |
|
| [Participation of the dopaminergic brain system in effects of glucocorticoid hormones]. | 2001 Jul |
|
| Dopamine D2 receptor mediated presynaptic inhibition of striatopallidal GABA(A) IPSCs in vitro. | 2001 Jul |
|
| A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. | 2001 Jul |
|
| Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum. | 2001 Jul 3 |
|
| [Pseudoneurotic schizophrenia: a case report]. | 2001 Jul-Aug |
|
| Pharmacological characterization of the D1- and D2-like dopamine receptors from the brain of the leopard frog, Rana pipiens. | 2001 Jun |
|
| The role of medial prefrontal cortical dopamine in spontaneous flexibility in the rat. | 2001 Jun |
|
| Hypericum perforatum as a nootropic drug: enhancement of retrieval memory of a passive avoidance conditioning paradigm in mice. | 2001 Jun |
|
| In vitro modulation of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area by antipsychotic drugs. | 2001 Jun |
|
| Dopamine D(2)-like receptors selectively block N-type Ca(2+) channels to reduce GABA release onto rat striatal cholinergic interneurones. | 2001 Jun 1 |
|
| Worsening of Parkinsonism after the use of veralipride for treatment of menopause: case report. | 2001 Mar |
|
| Suspected induction of a pyoderma gangrenosum-like eruption due to sulpiride treatment. | 2001 Mar |
|
| 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. | 2001 Mar |
|
| Intrapallidal D2 dopamine receptors control globus pallidus neuron activity in the rat. | 2001 Mar 9 |
|
| Electrophysiological effects of cocaethylene, cocaine, and ethanol on dopaminergic neurons of the ventral tegmental area. | 2001 May |
|
| Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. | 2001 Nov |
|
| Dopaminergic modulation of grooming behavior in virgin and pregnant rats. | 2001 Nov |
|
| Development of a high-performance liquid chromatographic method for bioanalytical applications with sulpiride. | 2001 Nov 5 |
|
| Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. | 2001 Oct |
|
| Changes in muscle tone are regulated by D1 and D2 dopamine receptors in the ventral striatum and D1 receptors in the substantia nigra. | 2001 Oct |
|
| Potentiation of opioid analgesia in dopamine2 receptor knock-out mice: evidence for a tonically active anti-opioid system. | 2001 Oct 1 |
|
| Hypothalamic CRH mRNA levels are differentially modulated by repeated 'binge' cocaine with or without D(1) dopamine receptor blockade. | 2001 Oct 19 |
|
| Physostigmine as treatment for severe CNS anticholinergic toxicity. | 2001 Sep |
|
| Dopamine D4 receptor activation inhibits presynaptically glutamatergic neurotransmission in the rat supraoptic nucleus. | 2001 Sep |
Sample Use Guides
400mg twice daily the doctor may reduce the dose to 200mg twice daily or increase it to a maximum of 1200mg twice daily
Route of Administration:
Oral
CHO-K1 D3R cells (DiscoveRx) were seeded at a density of 5000 cells/well in 384-well black, clear-bottom plates. Following 24 h of incubation, the cells were treated with multiple concentrations of the Sulpiride (0-10 μM) in Hanks’ balanced buffer solution containing 2% DMSO. Following a 10 min preincubation, the cells were next treated with an EC95 dose of dopamine (100 nM) and then incubated at 37 C for 90 min. DiscoveRx reagent (2.5) was then added to cells followed by a 60 min incubation at room temperature. Luminescence was measured on a Hamamatsu FDSS μ-cell reader.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:33:01 GMT 2023
by
admin
on
Sat Dec 16 11:33:01 GMT 2023
|
| Record UNII |
03U3QUS07J
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23694-14-6
Created by
admin on Sat Dec 16 11:33:01 GMT 2023 , Edited by admin on Sat Dec 16 11:33:01 GMT 2023
|
PRIMARY | |||
|
245-826-4
Created by
admin on Sat Dec 16 11:33:01 GMT 2023 , Edited by admin on Sat Dec 16 11:33:01 GMT 2023
|
PRIMARY | |||
|
DTXSID80946497
Created by
admin on Sat Dec 16 11:33:01 GMT 2023 , Edited by admin on Sat Dec 16 11:33:01 GMT 2023
|
PRIMARY | |||
|
74586-15-5
Created by
admin on Sat Dec 16 11:33:01 GMT 2023 , Edited by admin on Sat Dec 16 11:33:01 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
03U3QUS07J
Created by
admin on Sat Dec 16 11:33:01 GMT 2023 , Edited by admin on Sat Dec 16 11:33:01 GMT 2023
|
PRIMARY | |||
|
74686-71-8
Created by
admin on Sat Dec 16 11:33:01 GMT 2023 , Edited by admin on Sat Dec 16 11:33:01 GMT 2023
|
SUPERSEDED | |||
|
3015163
Created by
admin on Sat Dec 16 11:33:01 GMT 2023 , Edited by admin on Sat Dec 16 11:33:01 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
